LONDON, UK, and Atlanta, USA, 3 January 2008 -- SkyePharma PLC (LSE: SKP) and Sciele Pharma, Inc (NASDAQ: SCRX) announce that the U.S. Food and Drug Administration (FDA) has approved all four dosage strengths of the new Sular® formulation. Sular® is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented GEOMATRIX™technology, which provides a lower dose of Sular® for each of its current doses. The expected launch for the new Sular® formulation is during the first quarter of 2008.
